MetLife (MET) Stock Forecast, Price Target & Predictions
MET Stock Forecast
MetLife stock forecast is as follows: an average price target of $86.69 (represents a 13.78% upside from MET’s last price of $76.19) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
MET Price Target
The average price target for MetLife (MET) is $86.69 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $145.00 to $74.00. This represents a potential 13.78% upside from MET's last price of $76.19.
MET Analyst Ratings
According to 10 Wall Street analysts, MetLife's rating consensus is 'Buy'. The analyst rating breakdown for MET stock is 0 'Strong Buy' (0.00%), 10 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MetLife Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Alex Scott | Barclays | $91.00 | $77.52 | 17.39% | 19.44% |
| Aug 01, 2024 | Joshua Shanker | Bank of America Securities | $96.00 | $76.85 | 24.92% | 26.00% |
| Jul 10, 2024 | Bob Huang | Morgan Stanley | $83.00 | $69.92 | 18.71% | 8.94% |
| May 22, 2024 | Kevin Heal | Argus Research | $80.00 | $73.15 | 9.36% | 5.00% |
| May 06, 2024 | John Barnidge | Piper Sandler | $82.00 | $70.94 | 15.60% | 7.63% |
| Mar 13, 2024 | Catherine Seifert | CFRA | $77.00 | $72.67 | 5.96% | 1.06% |
| Jan 08, 2024 | Alex Scott | Goldman Sachs | $80.00 | $68.92 | 16.08% | 5.00% |
| Sep 14, 2023 | Brett Linzey | Mizuho Securities | $145.00 | $63.79 | 127.31% | 90.31% |
| Feb 02, 2023 | - | Morgan Stanley | $90.00 | $72.68 | 23.83% | 18.13% |
| Jan 10, 2023 | - | Morgan Stanley | $88.00 | $71.35 | 23.34% | 15.50% |
The latest MetLife stock forecast, released on Sep 04, 2024 by Alex Scott from Barclays, set a price target of $91.00, which represents a 17.39% increase from the stock price at the time of the forecast ($77.52), and a 19.44% increase from MET last price ($76.19).
MetLife Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 7 |
| Avg Price Target | $91.00 | $90.00 | $84.14 |
| Last Closing Price | $76.19 | $76.19 | $76.19 |
| Upside/Downside | 19.44% | 18.13% | 10.43% |
In the current month, the average price target of MetLife stock is $91.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 19.44% increase as opposed to MetLife's last price of $76.19. This month's average price target is up 1.11% compared to last quarter, and up 8.15% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 23, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 18, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 10, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 11, 2024 | Citigroup | Underperform | Underperform | Hold |
| Apr 05, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jan 08, 2024 | Goldman Sachs | Neutral | Buy | Upgrade |
| Sep 14, 2023 | Jefferies | - | Buy | Upgrade |
| Feb 02, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
MetLife's last stock rating was published by Wells Fargo on Aug 12, 2024. The company gave MET a "Overweight" rating, the same as its previous rate.
MetLife Financial Forecast
MetLife Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.87B | $16.62B | $15.39B | $16.32B | $22.27B | - | $1.16B | $19.17B | $15.23B | $15.86B | $14.28B | $19.71B | $15.44B |
| Avg Forecast | $22.28B | $21.58B | $21.15B | $19.34B | $21.04B | $20.69B | $19.92B | $19.01B | $19.83B | $19.40B | $18.87B | $18.19B | $18.88B | $18.55B | $18.57B | $17.73B | $18.46B | $17.68B | $16.91B | $16.84B | $17.22B | $20.58B | $16.04B | $16.78B | $17.67B | $16.28B | $15.84B | $16.03B | $16.21B | $16.00B |
| High Forecast | $23.10B | $22.38B | $21.93B | $20.06B | $21.81B | $21.45B | $20.65B | $19.72B | $20.56B | $20.11B | $19.56B | $18.86B | $19.58B | $19.08B | $19.25B | $18.38B | $19.42B | $18.62B | $17.54B | $17.46B | $17.85B | $21.34B | $16.04B | $17.58B | $18.52B | $17.06B | $16.60B | $16.80B | $16.99B | $16.77B |
| Low Forecast | $21.66B | $20.99B | $20.56B | $18.81B | $20.46B | $20.12B | $19.37B | $18.49B | $19.28B | $18.86B | $18.35B | $17.69B | $18.36B | $17.90B | $18.06B | $17.24B | $17.72B | $16.71B | $16.45B | $16.38B | $16.74B | $20.01B | $16.04B | $16.32B | $17.19B | $15.84B | $15.41B | $15.60B | $15.77B | $15.56B |
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 9 | 10 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.98% | 0.91% | 0.95% | 1.08% | - | 0.07% | 1.08% | 0.94% | 1.00% | 0.89% | 1.22% | 0.96% |
MetLife's average Quarter revenue forecast for Dec 23 based on 5 analysts is $18.46B, with a low forecast of $17.72B, and a high forecast of $19.42B. MET's average Quarter revenue forecast represents a 16.33% increase compared to the company's last Quarter revenue of $15.87B (Sep 23).
MetLife EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 9 | 10 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-78.00M | $-197.00M | $507.00M | $1.97B | $589.00M | - | $935.00M | $1.52B | $2.28B | $4.71B | $514.00M | $394.00M | $1.15B |
| Avg Forecast | $1.52B | $1.47B | $1.44B | $1.32B | $1.43B | $1.41B | $1.36B | $1.29B | $1.35B | $1.32B | $1.28B | $1.24B | $1.29B | $1.26B | $1.26B | $1.11B | $1.26B | $1.20B | $1.15B | $874.54M | $1.17B | $1.54B | $1.09B | $691.33M | $878.11M | $1.40B | $2.74B | $317.81M | $261.80M | $1.06B |
| High Forecast | $1.57B | $1.52B | $1.49B | $1.37B | $1.49B | $1.46B | $1.41B | $1.34B | $1.40B | $1.37B | $1.33B | $1.28B | $1.33B | $1.30B | $1.31B | $1.33B | $1.32B | $1.27B | $1.19B | $1.05B | $1.22B | $1.85B | $1.09B | $829.60M | $1.05B | $1.68B | $3.28B | $381.37M | $314.16M | $1.28B |
| Low Forecast | $1.47B | $1.43B | $1.40B | $1.28B | $1.39B | $1.37B | $1.32B | $1.26B | $1.31B | $1.28B | $1.25B | $1.20B | $1.25B | $1.22B | $1.23B | $885.03M | $1.21B | $1.14B | $1.12B | $699.63M | $1.14B | $1.23B | $1.09B | $553.07M | $702.49M | $1.12B | $2.19B | $254.25M | $209.44M | $850.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.06% | -0.17% | 0.58% | 1.68% | 0.38% | - | 1.35% | 1.74% | 1.62% | 1.72% | 1.62% | 1.50% | 1.08% |
3 analysts predict MET's average Quarter EBITDA for Jun 23 to be $1.15B, with a high of $1.19B and a low of $1.12B. This is 127.12% upper than MetLife's previous annual EBITDA (Mar 23) of $507.00M.
MetLife Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 9 | 10 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $489.00M | $402.00M | $80.00M | $1.34B | $395.00M | - | $669.00M | $1.21B | $1.58B | $3.41B | $358.00M | $158.00M | $706.00M |
| Avg Forecast | $2.28B | $2.26B | $2.17B | $1.91B | $2.03B | $2.03B | $1.97B | $1.73B | $1.86B | $1.85B | $1.78B | $1.57B | $1.67B | $1.61B | $1.50B | $791.56M | $1.34B | $1.39B | $1.36B | $625.74M | $1.19B | $1.07B | $1.06B | $494.65M | $694.31M | $976.16M | $1.98B | $221.35M | $104.99M | $653.38M |
| High Forecast | $2.39B | $2.37B | $2.27B | $2.00B | $2.12B | $2.12B | $2.06B | $1.81B | $1.95B | $1.94B | $1.86B | $1.64B | $1.75B | $1.70B | $1.58B | $949.87M | $1.44B | $1.54B | $1.42B | $750.89M | $1.25B | $1.29B | $1.06B | $593.59M | $833.17M | $1.17B | $2.37B | $265.62M | $125.98M | $784.05M |
| Low Forecast | $2.20B | $2.18B | $2.09B | $1.84B | $1.95B | $1.95B | $1.90B | $1.66B | $1.79B | $1.79B | $1.71B | $1.51B | $1.61B | $1.45B | $1.45B | $633.25M | $1.20B | $1.26B | $1.31B | $500.59M | $1.15B | $859.02M | $1.06B | $395.72M | $555.45M | $780.93M | $1.58B | $177.08M | $83.99M | $522.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.35% | 0.30% | 0.13% | 1.13% | 0.37% | - | 1.35% | 1.74% | 1.62% | 1.72% | 1.62% | 1.50% | 1.08% |
MetLife's average Quarter net income forecast for Dec 23 is $1.34B, with a range of $1.20B to $1.44B. MET's average Quarter net income forecast represents a 174.89% increase compared to the company's last Quarter net income of $489.00M (Sep 23).
MetLife SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 9 | 10 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.48B | $1.57B | $1.45B | - | $1.43B | $1.65B | $1.40B | $1.30B | $1.42B | $1.56B | $1.38B |
| Avg Forecast | $1.95B | $1.89B | $1.85B | $1.69B | $1.84B | $1.81B | $1.74B | $1.66B | $1.74B | $1.70B | $1.65B | $1.59B | $1.65B | $1.62B | $1.63B | $1.70B | $1.62B | $1.55B | $1.48B | $1.34B | $1.51B | $950.40M | $1.40B | $1.06B | $947.83M | $864.00M | $757.87M | $877.37M | $1.04B | $1.28B |
| High Forecast | $2.02B | $1.96B | $1.92B | $1.76B | $1.91B | $1.88B | $1.81B | $1.73B | $1.80B | $1.76B | $1.71B | $1.65B | $1.71B | $1.67B | $1.69B | $2.03B | $1.70B | $1.63B | $1.54B | $1.61B | $1.56B | $1.14B | $1.40B | $1.27B | $1.14B | $1.04B | $909.45M | $1.05B | $1.25B | $1.54B |
| Low Forecast | $1.90B | $1.84B | $1.80B | $1.65B | $1.79B | $1.76B | $1.70B | $1.62B | $1.69B | $1.65B | $1.61B | $1.55B | $1.61B | $1.57B | $1.58B | $1.36B | $1.55B | $1.46B | $1.44B | $1.07B | $1.47B | $760.32M | $1.40B | $847.64M | $758.27M | $691.20M | $606.30M | $701.89M | $831.39M | $1.02B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.04% | 1.53% | - | 1.35% | 1.74% | 1.62% | 1.72% | 1.62% | 1.50% | 1.08% |
MetLife's average Quarter SG&A projection for Jun 23 is $1.48B, based on 3 Wall Street analysts, with a range of $1.44B to $1.54B. The forecast indicates a 0.12% rise compared to MET last annual SG&A of $1.48B (Mar 23).
MetLife EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 9 | 10 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.56 | $0.48 | $0.02 | $1.69 | $0.42 | - | $0.74 | $1.44 | $1.78 | $3.85 | $0.33 | $0.14 | $0.70 |
| Avg Forecast | $3.19 | $3.17 | $3.04 | $2.67 | $2.84 | $2.83 | $2.76 | $2.42 | $2.60 | $2.60 | $2.49 | $2.19 | $2.34 | $2.25 | $2.10 | $1.84 | $1.88 | $1.94 | $1.90 | $1.81 | $1.67 | $1.18 | $1.45 | $1.65 | $1.47 | $1.74 | $1.68 | $1.53 | $1.52 | $1.61 |
| High Forecast | $3.35 | $3.32 | $3.18 | $2.80 | $2.97 | $2.97 | $2.89 | $2.53 | $2.73 | $2.72 | $2.61 | $2.30 | $2.45 | $2.38 | $2.20 | $1.93 | $2.02 | $2.16 | $1.99 | $1.90 | $1.75 | $1.24 | $1.45 | $1.75 | $1.56 | $1.84 | $1.79 | $1.63 | $1.61 | $1.71 |
| Low Forecast | $3.08 | $3.05 | $2.93 | $2.57 | $2.74 | $2.73 | $2.66 | $2.33 | $2.51 | $2.50 | $2.40 | $2.11 | $2.26 | $2.03 | $2.03 | $1.78 | $1.68 | $1.77 | $1.83 | $1.75 | $1.61 | $1.14 | $1.45 | $1.59 | $1.42 | $1.68 | $1.62 | $1.48 | $1.47 | $1.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.29% | 0.25% | 0.01% | 1.01% | 0.36% | - | 0.45% | 0.98% | 1.02% | 2.29% | 0.22% | 0.09% | 0.43% |
According to 5 Wall Street analysts, MetLife's projected average Quarter EPS for Dec 23 is $1.88, with a low estimate of $1.68 and a high estimate of $2.02. This represents a 235.86% increase compared to MET previous annual EPS of $0.56 (Sep 23).
MetLife Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LNC | Lincoln National | $29.45 | $53.73 | 82.44% | Hold |
| UNM | Unum Group | $55.02 | $64.60 | 17.41% | Buy |
| MET | MetLife | $76.19 | $86.69 | 13.78% | Buy |
| JXN | Jackson Financial | $83.60 | $92.67 | 10.85% | Hold |
| PRU | Prudential Financial | $116.26 | $115.30 | -0.83% | Buy |
| CNO | CNO Financial Group | $33.05 | $31.00 | -6.20% | Hold |
| MFC | Manulife Financial | $28.08 | $25.86 | -7.91% | Buy |
| GL | Globe Life | $103.80 | $94.00 | -9.44% | Hold |
| AFL | Aflac | $108.59 | $88.78 | -18.24% | Hold |
MET Forecast FAQ
Is MetLife a good buy?
Yes, according to 10 Wall Street analysts, MetLife (MET) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 100.00% of MET's total ratings.
What is MET's price target?
MetLife (MET) average price target is $86.69 with a range of $74 to $145, implying a 13.78% from its last price of $76.19. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MetLife stock go up soon?
According to Wall Street analysts' prediction for MET stock, the company can go up by 13.78% (from the last price of $76.19 to the average price target of $86.69), up by 90.31% based on the highest stock price target, and down by -2.87% based on the lowest stock price target.
Can MetLife stock reach $110?
MET's highest twelve months analyst stock price target of $145 supports the claim that MetLife can reach $110 in the near future.
What is MetLife's current price target trend?
1 Wall Street analyst forecast a $91 price target for MetLife (MET) this month, up 19.44% from its last price of $76.19. Compared to the last 3 and 12 months, the average price target increased by 18.13% and increased by 10.43%, respectively.
What are MetLife's analysts' financial forecasts?
MetLife's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $80.66B (high $83.63B, low $78.43B), average EBITDA is $5.49B (high $5.69B, low $5.34B), average net income is $7.75B (high $8.12B, low $7.47B), average SG&A $7.06B (high $7.32B, low $6.87B), and average EPS is $10.84 (high $11.36, low $10.46). MET's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $84.35B (high $87.46B, low $82.02B), average EBITDA is $5.74B (high $5.95B, low $5.58B), average net income is $8.62B (high $9.03B, low $8.31B), average SG&A $7.39B (high $7.66B, low $7.18B), and average EPS is $12.06 (high $12.64, low $11.63).
Did the MET's actual financial results beat the analysts' financial forecasts?
Based on MetLife's last annual report (Dec 2022), the company's revenue was $69.9B, which missed the average analysts forecast of $70.61B by -1.01%. Apple's EBITDA was $3.78B, missing the average prediction of $4.5B by -16.02%. The company's net income was $2.54B, missing the average estimation of $3.82B by -33.46%. Apple's SG&A was $5.89B, beating the average forecast of $4.92B by 19.70%. Lastly, the company's EPS was $2.93, missing the average prediction of $5.95 by -50.73%. In terms of the last quarterly report (Sep 2023), MetLife's revenue was $15.87B, missing the average analysts' forecast of $17.68B by -10.26%. The company's EBITDA was $-78M, missing the average prediction of $1.2B by -106.48%. MetLife's net income was $489M, missing the average estimation of $1.39B by -64.81%. The company's SG&A was $0, missing the average forecast of $1.55B by -100.00%. Lastly, the company's EPS was $0.56, missing the average prediction of $1.94 by -71.19%